Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedländer, Éric Pujade-Lauraine, Val Gebski et al.|The Lancet Oncology|2018Cited by 137
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSubotheni Thavaneswaran, David M. Thomas, Jayesh Desai et al.|npj Precision Oncology|2024Cited by 6
A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid HemangioendotheliomaGregory M. Coté, David M. Thomas, Mason Aberoumand et al.|Clinical Cancer Research|2026Cited by 3
Trastuzumab emtansine (T-DM1) in advanced cancers with <i>HER2 </i>mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Subotheni Thavaneswaran, David M. Thomas, Antony Mersiades et al.|Journal of Clinical Oncology|2023Cited by 2
996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14Frank Lin, D. Thomas, M. Itchins et al.|Annals of Oncology|2025Cited by 0